Wednesday, September 28, 2016 5:37:36 PM
All of the message Boards bashed NPHC back in 2009 at $0.02 with about 200M shares outstanding. Cobroxin hit the store shelves and the stock went to $0.80 - -- and stayed there for a while (with some bounces).
They have a lot more going for them now - including the possibility of an actual Phase II study on the near horizon. The current valuation is ridiculous by any measure.
So - I refuse to be negative and will keep adding to my position. I believe that we will be rewarded before the end of the year. My prediction: >$0.20 by the end of the year (higher if they announce the trials). JMHO
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM